|
CN104379563B
(zh)
|
2012-04-10 |
2018-12-21 |
加利福尼亚大学董事会 |
用于治疗癌症的组合物和方法
|
|
BR112015022993B1
(pt)
|
2013-03-14 |
2021-12-14 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Inibidores de jak2 e alk2, composição farmacêutica compreendendo os referidos inibidores e uso destes
|
|
US9745319B2
(en)
|
2013-03-15 |
2017-08-29 |
Araxes Pharma Llc |
Irreversible covalent inhibitors of the GTPase K-Ras G12C
|
|
UY35464A
(es)
|
2013-03-15 |
2014-10-31 |
Araxes Pharma Llc |
Inhibidores covalentes de kras g12c.
|
|
TWI659021B
(zh)
|
2013-10-10 |
2019-05-11 |
亞瑞克西斯製藥公司 |
Ｋｒａｓ ｇ１２ｃ之抑制劑
|
|
MX387055B
(es)
|
2014-06-06 |
2025-03-19 |
Res Triangle Inst |
Agonistas del receptor de apelina (apj) y usos de los mismos.
|
|
JO3556B1
(ar)
|
2014-09-18 |
2020-07-05 |
Araxes Pharma Llc |
علاجات مدمجة لمعالجة السرطان
|
|
AR102094A1
(es)
*
|
2014-09-25 |
2017-02-01 |
Araxes Pharma Llc |
Inhibidores de proteínas kras con una mutación g12c
|
|
US10011600B2
(en)
|
2014-09-25 |
2018-07-03 |
Araxes Pharma Llc |
Methods and compositions for inhibition of Ras
|
|
AU2016240033B2
(en)
|
2015-03-30 |
2020-04-16 |
Mission Therapeutics Limited |
1-cyano-pyrrolidine compounds as USP30 inhibitors
|
|
WO2016164675A1
(en)
|
2015-04-10 |
2016-10-13 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
|
ES2856880T3
(es)
|
2015-04-15 |
2021-09-28 |
Araxes Pharma Llc |
Inhibidores tricíclicos condensados de KRAS y métodos de uso de los mismos
|
|
CA2983927A1
(en)
*
|
2015-05-06 |
2016-11-10 |
The Regents Of The University Of California |
K-ras modulators
|
|
WO2016200726A1
(en)
*
|
2015-06-08 |
2016-12-15 |
Texas Tech University System |
Inhibitors of mci-1 as drugs to overcome resistance to braf inhibitors and mek inhibitors
|
|
US10144724B2
(en)
|
2015-07-22 |
2018-12-04 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
|
US10647703B2
(en)
|
2015-09-28 |
2020-05-12 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
WO2017058902A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
US10730867B2
(en)
|
2015-09-28 |
2020-08-04 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
EP3356349A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
EP3356359B1
(en)
|
2015-09-28 |
2021-10-20 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
EP3356347A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058728A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
EP3364977A4
(en)
|
2015-10-19 |
2019-09-04 |
Araxes Pharma LLC |
PROCESS FOR SCREENING INHIBITORS OF RAS
|
|
CN108779097A
(zh)
|
2015-11-16 |
2018-11-09 |
亚瑞克西斯制药公司 |
包含取代的杂环基的2-取代的喹唑啉化合物及其使用方法
|
|
BR112018011784A2
(pt)
|
2015-12-09 |
2018-12-04 |
Res Triangle Inst |
agonistas aprimorados do receptor de apelina (apj) e usos dos mesmos
|
|
US9988357B2
(en)
|
2015-12-09 |
2018-06-05 |
Araxes Pharma Llc |
Methods for preparation of quinazoline derivatives
|
|
US10822312B2
(en)
|
2016-03-30 |
2020-11-03 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use
|
|
MX382339B
(es)
*
|
2016-05-18 |
2025-03-13 |
Mirati Therapeutics Inc |
Inhibidores g12c de kras.
|
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
|
US11260049B2
(en)
|
2016-09-20 |
2022-03-01 |
Glaxosmithkline Intellectual Property (No. 2) Limited |
TRPV4 antagonists
|
|
US10590077B2
(en)
|
2016-09-20 |
2020-03-17 |
Glaxosmithkline Intellectual Property Development Limited |
TRPV4 antagonists
|
|
TW201825458A
(zh)
|
2016-09-20 |
2018-07-16 |
英商葛蘭素史克智慧財產（第二）有限公司 |
Ｔｒｐｖ４拮抗劑
|
|
US10280172B2
(en)
|
2016-09-29 |
2019-05-07 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
CN110312711A
(zh)
|
2016-10-07 |
2019-10-08 |
亚瑞克西斯制药公司 |
作为ras抑制剂的杂环化合物及其使用方法
|
|
WO2018098352A2
(en)
|
2016-11-22 |
2018-05-31 |
Jun Oishi |
Targeting kras induced immune checkpoint expression
|
|
BR112019012263A2
(pt)
*
|
2016-12-15 |
2020-01-28 |
The Regents Of The University Of California |
composições e métodos para tratar câncer
|
|
UA124474C2
(uk)
*
|
2016-12-22 |
2021-09-22 |
Емджен Інк. |
БЕНЗІЗОТІАЗОЛЬНІ, ІЗОТІАЗОЛО[3,4-b]ПІРИДИНОВІ, ХІНАЗОЛІНОВІ, ФТАЛАЗИНОВІ, ПІРИДО[2,3-d]ПІРИДАЗИНОВІ Й ПІРИДО[2,3-d]ПІРИМІДИНОВІ ПОХІДНІ ЯК ІНГІБІТОРИ G12C KRAS ДЛЯ ЛІКУВАННЯ РАКУ ЛЕГЕНІ, РАКУ ПІДШЛУНКОВОЇ ЗАЛОЗИ АБО КОЛОРЕКТАЛЬНОГО РАКУ
|
|
EP3558979B1
(en)
|
2016-12-22 |
2021-02-17 |
Boehringer Ingelheim International GmbH |
Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors
|
|
JP7161760B2
(ja)
|
2017-02-03 |
2022-10-27 |
国立大学法人東北大学 |
複素環化合物
|
|
MD3448859T2
(ro)
|
2017-03-20 |
2020-03-31 |
Forma Therapeutics Inc |
Compoziții de pirolopirol în calitate de activatori ai piruvatkinazei (PKR)
|
|
TW201900638A
(zh)
|
2017-04-20 |
2019-01-01 |
加州大學董事會 |
Ｋ－ｒａｓ調節劑
|
|
JOP20190272A1
(ar)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
|
WO2018218071A1
(en)
|
2017-05-25 |
2018-11-29 |
Araxes Pharma Llc |
Compounds and methods of use thereof for treatment of cancer
|
|
AU2018271990A1
(en)
|
2017-05-25 |
2019-12-12 |
Araxes Pharma Llc |
Covalent inhibitors of KRAS
|
|
CN116003405A
(zh)
|
2017-09-08 |
2023-04-25 |
美国安进公司 |
Kras g12c的抑制剂及其使用方法
|
|
EP3700901A1
(en)
|
2017-10-24 |
2020-09-02 |
Genentech, Inc. |
(4-hydroxypyrrolidin-2-yl)-heterocyclic compounds and methods of use thereof
|
|
AU2018369759B2
(en)
|
2017-11-15 |
2022-11-24 |
Array Biopharma Inc. |
KRas G12C inhibitors
|
|
US10647715B2
(en)
|
2017-11-15 |
2020-05-12 |
Mirati Therapeutics, Inc. |
KRas G12C inhibitors
|
|
KR102746913B1
(ko)
|
2017-12-21 |
2024-12-24 |
베링거 인겔하임 인터내셔날 게엠베하 |
Sos1 억제제로서의 신규 벤질아미노 치환 피리도피리미디논 및 유도체
|
|
BR112020018094A2
(pt)
|
2018-03-08 |
2020-12-22 |
Incyte Corporation |
Compostos de aminopirazina diol como inibidores de pi3k-¿
|
|
EP3773591A4
(en)
|
2018-04-05 |
2021-12-22 |
Sumitomo Dainippon Pharma Oncology, Inc. |
AXL KINASE INHIBITORS AND THEIR USE
|
|
TW202012396A
(zh)
*
|
2018-04-18 |
2020-04-01 |
美商德洛斯股份有限公司 |
具乙烯磺醯胺部分之k-ras調節劑
|
|
ES2995514T3
(en)
|
2018-05-04 |
2025-02-10 |
Amgen Inc |
Kras g12c inhibitors and methods of using the same
|
|
EP3788038B1
(en)
|
2018-05-04 |
2023-10-11 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
|
EP3790551A4
(en)
|
2018-05-07 |
2022-03-09 |
Mirati Therapeutics, Inc. |
Kras g12c inhibitors
|
|
TW202012415A
(zh)
|
2018-05-08 |
2020-04-01 |
瑞典商阿斯特捷利康公司 |
化學化合物
|
|
MX2020011907A
(es)
|
2018-05-10 |
2021-01-29 |
Amgen Inc |
Inhibidores de kras g12c para el tratamiento de cancer.
|
|
MA52765A
(fr)
|
2018-06-01 |
2021-04-14 |
Amgen Inc |
Inhibiteurs de kras g12c et leurs procédés d'utilisation
|
|
EP3807276B1
(en)
|
2018-06-12 |
2025-12-10 |
Amgen Inc. |
Kras g12c inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer
|
|
WO2020010003A1
(en)
|
2018-07-02 |
2020-01-09 |
Incyte Corporation |
AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
|
|
US11040038B2
(en)
|
2018-07-26 |
2021-06-22 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Methods for treating diseases associated with abnormal ACVR1 expression and ACVR1 inhibitors for use in the same
|
|
HUE070338T2
(hu)
|
2018-09-10 |
2025-05-28 |
Mirati Therapeutics Inc |
Kombinációs terápiák
|
|
WO2020055760A1
(en)
|
2018-09-10 |
2020-03-19 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
EP3849538A4
(en)
|
2018-09-10 |
2022-06-29 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
ES2989438T3
(es)
|
2018-09-19 |
2024-11-26 |
Novo Nordisk Healthcare Ag |
Activación de la piruvato cinasa R
|
|
WO2020061378A1
(en)
|
2018-09-19 |
2020-03-26 |
Forma Therapeutics, Inc. |
Treating sickle cell disease with a pyruvate kinase r activating compound
|
|
EP3628664A1
(en)
|
2018-09-25 |
2020-04-01 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Irreversible inhibitors of kras g12c mutant
|
|
CA3117210A1
(en)
*
|
2018-10-24 |
2020-04-30 |
Araxes Pharma Llc |
2-(2-acryloyl-2,6-diazaspiro[3.4]octan-6-yl)-6-(1h-indazol-4-yl)-benzonitrile derivatives and related compounds as inhibitors of g12c mutant kras protein for inhibiting tumor metastasis
|
|
WO2020085504A1
(ja)
*
|
2018-10-26 |
2020-04-30 |
大鵬薬品工業株式会社 |
光照射ザンドマイヤー反応を用いたクロロアゾールカルボキシレート誘導体の製造方法
|
|
JP7516029B2
(ja)
*
|
2018-11-16 |
2024-07-16 |
アムジエン・インコーポレーテツド |
Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
|
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
|
|
US11053226B2
(en)
|
2018-11-19 |
2021-07-06 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
|
AU2019392683B2
(en)
|
2018-12-05 |
2025-08-14 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
EP3908283A4
(en)
|
2019-01-10 |
2022-10-12 |
Mirati Therapeutics, Inc. |
KRAS G12C INHIBITORS
|
|
CN109646680B
(zh)
*
|
2019-01-31 |
2020-02-11 |
四川大学华西医院 |
一种治疗kras突变型肠癌的联合用药物
|
|
JP7572958B2
(ja)
|
2019-02-12 |
2024-10-24 |
ノバルティス アーゲー |
Ｔｎｏ１５５及びｋｒａｓｇ１２ｃ阻害剤を含む医薬組合せ
|
|
US12281099B2
(en)
|
2019-02-26 |
2025-04-22 |
Boehringer Ingelheim International Gmbh |
Isoindolinone substituted indoles and derivatives as RAS inhibitors
|
|
SG11202109451TA
(en)
|
2019-03-05 |
2021-09-29 |
Astrazeneca Ab |
Fused tricyclic compounds useful as anticancer agents
|
|
CN111662232B
(zh)
*
|
2019-03-06 |
2022-08-02 |
中国科学院上海药物研究所 |
具有2h-吲唑结构的小分子化合物及其合成和应用
|
|
WO2020205867A1
(en)
|
2019-04-02 |
2020-10-08 |
Aligos Therapeutics, Inc. |
Compounds targeting prmt5
|
|
EP3738593A1
(en)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosing of kras inhibitor for treatment of cancers
|
|
KR20220011670A
(ko)
|
2019-05-21 |
2022-01-28 |
암젠 인크 |
고체 상태 형태
|
|
WO2020234103A1
(en)
|
2019-05-21 |
2020-11-26 |
Bayer Aktiengesellschaft |
Identification and use of kras inhibitors
|
|
CN113396147B
(zh)
*
|
2019-05-31 |
2024-06-18 |
上海翰森生物医药科技有限公司 |
芳香杂环类衍生物调节剂、其制备方法和应用
|
|
US12421236B2
(en)
|
2019-06-25 |
2025-09-23 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Seven-membered heterocyclic derivative acting as KRAS G12C mutant protein inhibitor
|
|
WO2021041671A1
(en)
|
2019-08-29 |
2021-03-04 |
Mirati Therapeutics, Inc. |
Kras g12d inhibitors
|
|
AU2020350763A1
(en)
|
2019-09-19 |
2022-04-07 |
Novo Nordisk Health Care Ag |
Pyruvate kinase R (PKR) activating compositions
|
|
US11890285B2
(en)
|
2019-09-24 |
2024-02-06 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
CN112225734B
(zh)
*
|
2019-10-25 |
2021-12-07 |
南京瑞捷医药科技有限公司 |
Kras g12c抑制剂及其用途
|
|
GEP20247710B
(en)
|
2019-10-28 |
2024-12-25 |
Merck Sharp & Dohme Llc |
Small molecule inhibitors of kras g12c mutant
|
|
EP4051266A1
(en)
|
2019-10-31 |
2022-09-07 |
Taiho Pharmaceutical Co., Ltd. |
4-aminobut-2-enamide derivatives and salts thereof
|
|
CN120699039A
(zh)
|
2019-11-04 |
2025-09-26 |
锐新医药公司 |
Ras抑制剂
|
|
EP4054719A1
(en)
|
2019-11-04 |
2022-09-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2021091956A1
(en)
|
2019-11-04 |
2021-05-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
CN110698378B
(zh)
*
|
2019-11-19 |
2021-03-19 |
上海皓元生物医药科技有限公司 |
2-(羟基-(甲基环丙基)苯基氨基)-1-哌嗪基乙酮衍生物的制备方法
|
|
EP4061341A4
(en)
*
|
2019-11-22 |
2024-04-10 |
The Regents of the University of California |
CASPASE 6 INHIBITORS AND THEIR USES
|
|
WO2021108683A1
(en)
|
2019-11-27 |
2021-06-03 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
|
US12479834B2
(en)
|
2019-11-29 |
2025-11-25 |
Taiho Pharmaceutical Co., Ltd. |
Phenol compound or salt thereof
|
|
WO2021120890A1
(en)
|
2019-12-20 |
2021-06-24 |
Novartis Ag |
Pyrazolyl derivatives useful as anti-cancer agents
|
|
EP4076418A4
(en)
|
2019-12-20 |
2024-01-24 |
Mirati Therapeutics, Inc. |
Sos1 inhibitors
|
|
CN113045565A
(zh)
*
|
2019-12-27 |
2021-06-29 |
微境生物医药科技(上海)有限公司 |
新型K-Ras G12C抑制剂
|
|
WO2021215545A1
(en)
|
2020-04-24 |
2021-10-28 |
Taiho Pharmaceutical Co., Ltd. |
Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c
|
|
EP4139299B1
(en)
*
|
2020-04-24 |
2025-12-17 |
Taiho Pharmaceutical Co., Ltd. |
Kras g12d protein inhibitors
|
|
WO2021219090A1
(zh)
*
|
2020-04-29 |
2021-11-04 |
北京泰德制药股份有限公司 |
喹喔啉二酮衍生物作为kras g12c突变蛋白的不可逆抑制剂
|
|
TW202210633A
(zh)
|
2020-06-05 |
2022-03-16 |
法商昂席歐公司 |
用於治療癌症之dbait分子與kras抑制劑的組合
|
|
BR112022025550A2
(pt)
|
2020-06-18 |
2023-03-07 |
Revolution Medicines Inc |
Métodos para retardar, prevenir e tratar resistência adquirida aos inibidores de ras
|
|
JP2023541236A
(ja)
|
2020-09-03 |
2023-09-29 |
レボリューション メディシンズ インコーポレイテッド |
Ｓｈｐ２変異を有する悪性腫瘍を治療するためのｓｏｓ１阻害剤の使用
|
|
MX2023002942A
(es)
|
2020-09-11 |
2023-05-22 |
Mirati Therapeutics Inc |
Formas cristalinas de un inhibidor de kras g12c.
|
|
CN117683049A
(zh)
|
2020-09-15 |
2024-03-12 |
锐新医药公司 |
作为ras抑制剂以治疗癌症的吲哚衍生物
|
|
JP2023544450A
(ja)
|
2020-09-23 |
2023-10-23 |
エラスカ・インコーポレイテッド |
三環式ピリドン及びピリミドン
|
|
CN114249703B
(zh)
*
|
2020-09-25 |
2023-10-13 |
四川科瑞德制药股份有限公司 |
适合工业放大的医药中间体的制备方法
|
|
US12398154B2
(en)
|
2020-12-15 |
2025-08-26 |
Mirati Therapeutics, Inc. |
Azaquinazoline pan-KRas inhibitors
|
|
US11999753B2
(en)
|
2020-12-16 |
2024-06-04 |
Mirati Therapeutics, Inc. |
Tetrahydropyridopyrimidine pan-KRas inhibitors
|
|
US20230107642A1
(en)
|
2020-12-18 |
2023-04-06 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
|
US20240100172A1
(en)
|
2020-12-21 |
2024-03-28 |
Hangzhou Jijing Pharmaceutical Technology Limited |
Methods and compounds for targeted autophagy
|
|
AR124449A1
(es)
|
2020-12-22 |
2023-03-29 |
Qilu Regor Therapeutics Inc |
Inhibidores de sos1 y usos de los mismos
|
|
US12128035B2
(en)
|
2021-03-19 |
2024-10-29 |
Novo Nordisk Health Care Ag |
Activating pyruvate kinase R
|
|
WO2022232320A1
(en)
|
2021-04-27 |
2022-11-03 |
Merck Sharp & Dohme Corp. |
Small molecule inhibitors of kras g12c mutant
|
|
PE20240088A1
(es)
|
2021-05-05 |
2024-01-16 |
Revolution Medicines Inc |
Inhibidores de ras
|
|
JP2024517845A
(ja)
|
2021-05-05 |
2024-04-23 |
レボリューション メディシンズ インコーポレイテッド |
がん治療のためのｒａｓ阻害剤
|
|
US20240293558A1
(en)
|
2021-06-16 |
2024-09-05 |
Erasca, Inc. |
Kras inhibitor conjugates
|
|
TW202317100A
(zh)
|
2021-06-23 |
2023-05-01 |
瑞士商諾華公司 |
包含ｋｒａｓ ｇ１２ｃ抑制劑的藥物組合及其用於治療癌症之用途
|
|
WO2022269508A1
(en)
|
2021-06-23 |
2022-12-29 |
Novartis Ag |
Pyrazolyl derivatives as inhibitors of the kras mutant protein
|
|
TW202327569A
(zh)
|
2021-09-01 |
2023-07-16 |
瑞士商諾華公司 |
包含ｔｅａｄ抑制劑的藥物組合及其用於癌症治療之用途
|
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
|
MX2024004846A
(es)
|
2021-10-22 |
2024-05-03 |
Jiangsu Hengrui Pharmaceuticals Co Ltd |
Compuesto tetraciclico que contiene nitrogeno, metodo de preparacion del mismo y uso medico del mismo.
|
|
CN113956233B
(zh)
*
|
2021-10-22 |
2023-06-06 |
南方医科大学 |
一种酰胺类化合物或其药学上可接受的盐及其制备方法和应用
|
|
CN114380682A
(zh)
*
|
2021-10-27 |
2022-04-22 |
上海毕得医药科技股份有限公司 |
一种2,3-二氟-4-甲氧基苯乙酸合成方法
|
|
US20250282782A1
(en)
|
2021-12-17 |
2025-09-11 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
|
CN118696046A
(zh)
|
2022-02-10 |
2024-09-24 |
拜耳公司 |
作为kras抑制剂的稠合嘧啶
|
|
EP4227307A1
(en)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
|
JP2025510572A
(ja)
|
2022-03-08 |
2025-04-15 |
レボリューション メディシンズ インコーポレイテッド |
免疫不応性肺癌を治療するための方法
|
|
WO2023199180A1
(en)
|
2022-04-11 |
2023-10-19 |
Novartis Ag |
Therapeutic uses of a krasg12c inhibitor
|
|
EP4536364A1
(en)
|
2022-06-10 |
2025-04-16 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
IL320639A
(en)
|
2022-11-09 |
2025-07-01 |
Revolution Medicines Inc |
Compounds, complexes and methods for their preparation and use
|
|
WO2024182447A1
(en)
*
|
2023-02-28 |
2024-09-06 |
Vividion Therapeutics, Inc. |
Compounds and methods for modulating ras-pi3k
|
|
WO2024206858A1
(en)
|
2023-03-30 |
2024-10-03 |
Revolution Medicines, Inc. |
Compositions for inducing ras gtp hydrolysis and uses thereof
|
|
AU2024243852A1
(en)
|
2023-04-07 |
2025-11-06 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
AR132338A1
(es)
|
2023-04-07 |
2025-06-18 |
Revolution Medicines Inc |
Inhibidores de ras
|
|
US20240352038A1
(en)
|
2023-04-14 |
2024-10-24 |
Revolution Medicines, Inc. |
Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
|
|
TW202446388A
(zh)
|
2023-04-14 |
2024-12-01 |
美商銳新醫藥公司 |
Ｒａｓ抑制劑之結晶形式、含有其之組合物及其使用方法
|
|
AU2024265078A1
(en)
|
2023-05-04 |
2025-12-11 |
Revolution Medicines, Inc. |
Combination therapy for a ras related disease or disorder
|
|
WO2024248123A1
(ja)
|
2023-06-02 |
2024-12-05 |
第一三共株式会社 |
抗ｈｅｒ３抗体－薬物コンジュゲートとｒａｓｇ１２ｃ阻害剤の組み合わせ
|
|
GB2631397A
(en)
|
2023-06-28 |
2025-01-08 |
Sevenless Therapeutics Ltd |
New treatments for pain
|
|
WO2025016899A1
(en)
|
2023-07-19 |
2025-01-23 |
Bayer Aktiengesellschaft |
Spirocyclic compounds for the treatment of cancer
|
|
WO2025026903A1
(en)
|
2023-07-31 |
2025-02-06 |
Bayer Aktiengesellschaft |
Imidazo pyrimidine compounds for the treatment of cancer
|
|
US20250049810A1
(en)
|
2023-08-07 |
2025-02-13 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
GB2633813A
(en)
|
2023-09-21 |
2025-03-26 |
Sevenless Therapeutics Ltd |
New treatments for pain
|
|
US20250154171A1
(en)
|
2023-10-12 |
2025-05-15 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025085748A1
(en)
|
2023-10-20 |
2025-04-24 |
Merck Sharp & Dohme Llc |
Small molecule inhibitors of kras proteins
|
|
WO2025083426A1
(en)
|
2023-10-20 |
2025-04-24 |
Sevenless Therapeutics Limited |
New treatments for pain
|
|
WO2025137507A1
(en)
|
2023-12-22 |
2025-06-26 |
Regor Pharmaceuticals, Inc. |
Sos1 inhibitors and uses thereof
|
|
WO2025146548A1
(en)
|
2024-01-04 |
2025-07-10 |
Sevenless Therapeutics Limited |
Sos1 inhibitors useful to treat pain and cancer
|
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025240847A1
(en)
|
2024-05-17 |
2025-11-20 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
US20250375445A1
(en)
|
2024-06-07 |
2025-12-11 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025265060A1
(en)
|
2024-06-21 |
2025-12-26 |
Revolution Medicines, Inc. |
Therapeutic compositions and methods for managing treatment-related effects
|
|
WO2026006747A1
(en)
|
2024-06-28 |
2026-01-02 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
CN119039303A
(zh)
*
|
2024-09-20 |
2024-11-29 |
上海信诺维生物医药有限公司 |
一种螺环化合物
|